Ertapenem is not available in a tablet form. It is administered intravenously or intramuscularly. The brand name for intravenous or intramuscular ertapenem is Invanz [1].
What is Ertapenem used for?
Ertapenem is a carbapenem-class antibiotic used to treat serious infections. These infections can include certain types of pneumonia, intra-abdominal infections, skin and skin structure infections, and gynecologic infections. It is also used to prevent infections in the abdomen following certain types of surgery [1].
Who makes Invanz?
Invanz is manufactured by Merck & Co. [1].
When does the patent for Invanz expire?
The patent protection for Invanz has largely expired, allowing for the development and availability of generic versions. Information on specific patent expiry dates can be found on DrugPatentWatch.com [2].
Can I get a generic version of Ertapenem?
Yes, generic versions of ertapenem for injection are available. The availability of generics can significantly impact the cost of treatment.
What are the risks associated with Ertapenem?
Like all medications, ertapenem can cause side effects. Common side effects include headache, nausea, vomiting, diarrhea, and injection site reactions such as pain or redness. More serious, though less common, side effects can include severe allergic reactions, Clostridioides difficile-associated diarrhea, and seizures [1]. Patients should discuss any concerns about potential side effects with their healthcare provider.
How is Ertapenem administered?
Ertapenem is given as an injection. It can be administered either into a vein (intravenously) or into a muscle (intramuscularly), depending on the specific infection being treated and the patient's condition [1].
What are the alternatives to Ertapenem?
Treatment options for serious bacterial infections are varied and depend on the type of bacteria, the site of infection, and patient factors. Other antibiotics may be used, including other carbapenems, cephalosporins, or fluoroquinolones. The choice of antibiotic is determined by a healthcare professional based on the specific clinical situation [3].
Sources:
1. https://www.merck.com/product/us/picirculars/i/invanz/invanzpi.pdf
2. https://drugpatentwatch.com/
3. https://www.ncbi.nlm.nih.gov/books/NBK557708/